TrialHepatology (Baltimore, Md.)2018

Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.

Fred Poordad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.